Valuation: Nexstim Oyj

Market Cap 74.69M 86.24M 69.63M 64.04M 121M 8.2B 122M 818M 321M 4.1B 324M 317M 13.59B P/E 2026 *
77.1x
P/E 2027 * 34.3x
Enterprise Value 72.59M 83.82M 67.67M 62.24M 117M 7.97B 119M 795M 312M 3.99B 315M 308M 13.21B EV / Sales 2026 *
5.72x
EV / Sales 2027 * 4.41x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 10/02/2020
Director of Finance/CFO 40 10/02/2020
Chief Tech/Sci/R&D Officer 65 31/12/2007
Director TitleAgeSince
Director/Board Member 64 10/11/2019
Chairman 63 10/11/2019
Director/Board Member 55 30/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%-5.73% - - 87.51M
+2.32%+0.25%+23.85%+5.32% 209B
+2.51%+0.31%+1.11%-21.63% 137B
+1.88%+3.70%-22.38%+21.30% 130B
-2.75%+3.65%-55.30%-5.88% 71.14B
-0.70%+6.32%+11.09%+11.84% 51.59B
+0.62%+9.24%-15.14%-20.39% 49.99B
+1.37%+0.41%+22.88%+11.73% 39.31B
+0.99%+4.19%+40.06%+37.98% 38.89B
+0.40%+7.21%-23.13%+24.98% 32.19B
Average -0.08%+3.19%-1.88%+7.25% 84.33B
Weighted average by Cap. +1.13%+1.42%-0.24%+3.74%

Financials

2026 *2027 *
Net sales 12.7M 14.66M 11.84M 10.89M 20.56M 1.39B 20.79M 139M 54.6M 698M 55.07M 53.86M 2.31B 16.1M 18.59M 15.01M 13.8M 26.06M 1.77B 26.35M 176M 69.22M 884M 69.82M 68.28M 2.93B
Net income 1M 1.15M 932K 857K 1.62M 110M 1.64M 10.95M 4.3M 54.93M 4.34M 4.24M 182M 2.2M 2.54M 2.05M 1.89M 3.56M 242M 3.6M 24.1M 9.46M 121M 9.54M 9.33M 400M
Net Debt -2.1M -2.42M -1.96M -1.8M -3.4M -231M -3.44M -23M -9.03M -115M -9.11M -8.91M -382M -3.7M -4.27M -3.45M -3.17M -5.99M -406M -6.06M -40.53M -15.91M -203M -16.04M -15.69M -673M
Logo Nexstim Oyj
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-